Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker 3.3)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly


Our new policy concerning data sharing

All papers submitted to Adv Clin Exp Med since August 15, 2024, will be subject to our new policy concerning data sharing.

Adv Clin Exp Med requires the Authors of all original papers to make all data necessary to replicate the results of their study publicly available without restriction when the paper is submitted to the journal (relevant information must be registered in the Editorial System at the time of submission). The following provisions apply only to original papers (including research letters). They do not apply to reviews and meta-analyses.

All the data and related metadata underlying the reported findings should be deposited in appropriate public data repositories unless already provided as part of the submitted article. Authors must deposit the data when submitting the paper to the journal. It is not permitted to deposit the dataset after the manuscript has been accepted for publication.

Authors should provide in their paper the original data generated in the research process, and report any secondary data reuse that supports their results and analyses. Authors are not required to submit their entire dataset if only a portion of the data was used in the reported study. Also, Authors do not need to submit the raw data collected during an investigation if the standard in the field is to include data that have been processed. However, Authors have to share via an appropriate repository the basic dataset (both raw and processed, if the latter includes elaborated tables or figures that cannot be published as part of the article) necessary to replicate all the study findings reported in the article, as well as the related metadata.

Papers not including any declaration concerning data sharing will not enter peer review until such declaration is provided.

Accordingly, Authors should not upload in the Editorial System any supplementary files with relevant data. All supplementary files referred to in the manuscript (supplementary tables, supplementary figures and others) must be a part of the shared dataset deposited in the repository).

The declaration of data availability from the corresponding author on reasonable request will not be accepted beginning from August 15, 2024, unless exceptions discussed below occur.



Why is data sharing important?

Data sharing fosters scientific progress. Data availability allows and facilitates:

  • linking the findings and the supporting evidence
  • validation, replication, reanalysis, new analysis, reinterpretation of data, or their inclusion into meta-analyses;
  • reproducibility of research;
  • verification of methodology and reporting standards;
  • data archiving, thus increasing the value of the investment made in funding scientific research;
  • reduction of the burden on Authors in preserving and finding old data, and managing data access requests;
  • citation and linking of research data and their associated articles, enhancing visibility and ensuring recognition for Authors, data producers and curators.


Our Journal Citation Indicator (JCI)

The value of JCI for the year 2023 for Advances in Clinical and Experimental Medicine is 0.4 – and increase from the value for 2022, which was 0.38.

The Journal Citation Indicator is the average Category Normalized Citation Impact (CNCI) of citable items (articles & reviews) published by a journal over a recent three year period. The value of the Journal Citation Indicator is the mean CNCI for all articles and reviews published in a journal in the preceding three years. For example, for the 2020 Journal Citation Indicator value, the years under analysis are 2017, 2018 and 2019. As in the CNCI measurement, the Journal Citation Indicator calculation controls for different fields, document types (articles, reviews, etc.) and year of publication. The resulting number represents the relative citation impact of a given paper as the ratio of citations compared to a global baseline.

The Journal Citation Indicator is designed to complement the JIF – the original and longstanding metric for journal evaluation – and other metrics currently used in the research community. In addition to the use of normalization, there are several key differences between the Journal Citation Indicator and the JIF. For example, the Journal Citation Indicator’s calculation on three years of publications contrasts with the two-year window employed for the JIF. This three-year calculation enables the Journal Citation Indicator to be as current as possible, while also allowing more time for publications to accrue citations.

Also, the JIF calculation is based on citations made in the current year, while the Journal Citation Indicator counts citations from any time period following publication, up to the end of the current year.

14th Scientific and Training Conference of the Polish Society of Toxicology

In 2023, the Management Board of the Polish Society of Toxicology entrusted the organization of the next Conference to the Poznań Branch and the Wrocław Branch of the Polish Toxicological Society, therefore we have the honor to invite you to participate in: the 14th Scientific and Training Conference of the Polish Society of Toxicology entitled "Prospects and challenges of contemporary toxicology", which will be held in Poznań on September 4–6, 2024.  

The title of the conference covers a wide thematic scope consistent with the interdisciplinary nature of toxicology as a science, and the planned sessions will concern: experimental, molecular and genetic toxicology, in vitro, nanotoxicology, toxicological analysis, clinical, forensic and addiction toxicology, also veterinary, industrial, environmental, food and cosmetics toxicology.

We cordially invite and encourage members of the Polish Society of Toxicology, Young Scientists and Students, as well as all people interested in this topic, to participate in the Conference. Toxicology brings together people of science and practice.

We invite you to share the results of your research both in the form of oral presentations and poster sessions, and we provide prizes for the authors of the best works. We offer interesting lectures, plenary sessions and workshops.

The General Meeting of Delegates of the Polish Toxicological Society will also be held during the Conference.

Participating in the Conference is a great opportunity to exchange experiences and share knowledge, it is an opportunity to meet proven friends and good acquaintances and meet new ones, as well as an opportunity to establish scientific contacts and look for potential partners to jointly implement future research projects.

We hope that the time spent together during the Conference will be an excellent opportunity for all of us to discuss the latest trends, challenges and prospects for modern toxicology.

We count on your presence, inspiring lectures and presentations, and fruitful discussions.




Change in the rules of incentive for reviewers

Since January 1, 2021, our Reviewers receive 5 points for each review prepared for our journal.

A total of 20 points allows them to publish an article in Advances in Clinical and Experimental Medicine free of charge, provided that they are the first or the last author of a given article.

Since July 1, 2024, The points are valid for 2 years (24 months) counting from the day when a paper authored by our reviewer is initially accepted for publication and a requirement for paying APC appears (e.g., when the paper was initially accepted on July 1, 2024, 20 points must have been amassed within previous 24 months, that is from July 1, 2022, to June 30, 2024).

If an author knows or supposes that they are eligible for APC waiver, they should contact the Managing Editor: [alternative e-mail for Chinese authors:] – the Editorial System does not always remind editors about such eligibility.


New Impact Factor

According to Journal Citation Reports 2024 released on June 20, 2024, the journal Advances in Clinical and Experimental Medicine retained the Impact Factor (IF) of 2.1. It may not sound impressive, but in fact, it is so – in such a dynamic (not always in a positive sense) environment like scientific publishing receiving stably high evaluation results from the most regarded institution – Clarivate – is a proof of constantly satisfying performance and considerable scientific reliability. This is also shown by another parameter – in the category Medicine, Research & Experimental, we moved into the 3rd quartile (Q3; 118/189). It is worth emphasizing that for the first time our journal is listed in Q3 in this highly competitive group. Most of the top scientific medical journals are listed in this category because they all include original experimental papers in each issue. Moving upward in such environment (with a stable IF at the same time) is an unquestionable success.

The Scopus indices confirm that retaining high Impact Factor value reflects reality: CiteScore has increased from 3/4 to 3.7, while the journal is listed Q1 in the category Reviews and References, and Q2 in the category Medicine (miscellaneous), Biochemistry, Genetics and Molecular Biology. Both the IF and the Scopus indices clearly shows that our position within the scientific journals’ community has strengthened – we publish more and more cutting-edge research and our papers are cited in other prestigious scientific journals. We are striving and will be striving to make it even higher!

Special thanks go to all our authors, reviewers and section editors, whose hard work, commitment and competence have made this achievement possible. Disseminating science is a mission; the journal Advances in Clinical and Experimental Medicine is a part of a great project of making people in the whole world healthier and happier!



New call for submissions

Revolutionizing Cancer Treatment: Navigating the Intricate Landscape of Cellular Signaling Networks


Handling Editors

Prof. Hao Zhang (Department of Neurosurgery, The Second Affiliated Hospital, Chongqing Medical University) [].


Cancer arises from disruptions in the intricate cell signaling networks that drive tumor cell behavior. Chemotherapy and immunotherapy are the main cancer treatment approaches, but the complexity of these signaling networks often hinders the success of targeted therapies. Understanding the cell signaling networks involved in cancer development and progression is crucial. Challenges like drug resistance and metastasis underscore the need for novel approaches targeting key signaling networks for more effective cancer treatment.

Immunotherapy has shown promise by stimulating the patient's immune system but only benefits a subset of patients. Current research has identified many signaling pathways influencing cancer cell growth, spread, and drug resistance. However, the complexity of these signaling networks limits the successful clinical application of individual molecular targets. An in-depth understanding of the functions and regulation of key signaling networks associated with tumor progression is essential to develop new chemotherapies and targeted treatments.


This research initiative seeks submissions on topics like:

  1. Immune regulatory networks influencing cancer progression and prognosis
  2. Signaling pathways involved in cancer initiation and metastasis
  3. Biomarkers for predicting responses to immunotherapy and chemotherapy
  4. Crucial cell signaling networks governing immune responses
  5. Using multi-omics to reveal critical cancer signaling networks



signaling networks, cancer treatment, biomarker, immune response, immunotherapy, multi-omics, cancer progression and prognosis


Submission process

As a first step, we ask for submissions of an Expression of Interest with an Abstract of original papers outlining the themes above to Adv Clin Exp Med Managing Editor Marek Misiak [].

The Editor-in-Chief will review all submissions and select those invited to submit a full paper. The submission process will follow the regular Adv Clin Exp Med online process. All manuscripts will be sent to at least two independent reviewers.


Dates and fees

Submission of Expression of Interest until December 31, 2024, to the ACEM Managing Editor [];

Invitation to submit the full paper by January 31, 2025;

Submission of full paper by December 31, 2025.

If the paper is accepted, Authors will be required to pay a fee to cover publication costs ( For selected Authors (outstanding experts), reducing or even cancelling the publication fee is possible.


New Cite Score!

We proudly inform our readers that our Scopus CiteScore has increased from 3.4 for 2022 to 3.7 for 2023. Our current Scimago Journal Rank (SJR) is 0.535 and Source Normalized Impact Paper (SNIP) is 0.610. Steadily rising bibliometric scores of Advances in Clinical and Experimental Medicine confirm our expanding influence among scientific medical journals. CiteScore Tracker is also higher than a year before – 2.6 in June 2023 and 3.3 in June 2024.


Our copyright declaration


The Author/Author(s) declare that:


a) they are copyright holders to the scientific work/publication;

b) they are entitled to dispose of copyright for the purposes of the concluded license/publishing agreement with the Wroclaw Medical University;

c) they created the work/publication on their own;

d) the work/publication does not violate the rights of third parties.

In the event that a third party files a claim against Wroclaw Medical University as a result of the inconsistency of the Author's statements or assurances, the Author is obliged to immediately cover the full amount of all damages, costs, and expenses incurred by Wroclaw Medical University in connection with such claims. This includes damages and costs awarded by a competent court or resulting from the content of the settlement concluded with the aggrieved party, as well as costs of legal services.


Our rules concerning usage of AI tools

These guidelines refer only to the writing process (i.e., generating text using an AI tool), and not to the use of AI tools to analyze and draw insights from data as part of the research process. They do not apply to the use of basic tools for checking grammar, spelling, references etc.

Authors are allowed to use generative AI and AI-assisted technologies in the writing process before submission, but only to improve the language and readability of their paper and with the appropriate disclosure. Applying the technology should be done with human oversight and control, and authors should carefully review and edit the result, as AI can generate authoritative-sounding output that can be incorrect, incomplete or biased. AI and AI-assisted technologies should not be listed as an author or co-author, or be cited as an author. Authorship implies responsibilities and tasks that can only be attributed to and performed by humans. Please note that authors are ultimately responsible and accountable for the contents of the work.

Detailed information should be provided in the methods section: The full prompt used in the production of the work, as well as the AI tool and its version, should be disclosed. Authors are accountable for the accuracy of the work and for ensuring that there is no plagiarism. They must also ensure that all sources are appropriately cited and should carefully review the work to guard against bias that may be introduced by AI. Editors may decline to move forward with manuscripts if AI is used inappropriately.

Authors who use AI-assisted technologies as aids in the writing of the manuscript should note this in the cover letter and in the acknowledgments section of the manuscript. Moreover, they must disclose the use of generative AI and AI-assisted technologies by adding a statement at the end of their manuscript in the manuscript body (main text) file, at the end of the paper. Such statement will appear in the published work.

The statement should be placed in a new section entitled “AI usage in the writing process” and follow this pattern:

During the preparation of this work the author(s) used [NAME TOOL / SERVICE] in order to [REASON]. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.

If there is nothing to disclose, there is no need to add a statement.

Adv Clin Exp Med does not permit the use of generative AI or AI-assisted tools to create or alter images in submitted manuscripts. This may include enhancing, obscuring, moving, removing, or introducing a specific feature within an image or figure. Adjustments of brightness, contrast, or color balance are acceptable if they do not obscure or eliminate any information present in the original. Image forensics tools or specialized software might be applied to submitted manuscripts to identify suspected image irregularities.

The only exception is if the use of AI or AI-assisted tools is part of the research design or research methods (such as in AI-assisted imaging approaches to generate or interpret the underlying research data, for example in the field of biomedical imaging). If this is done, such use must be described in a reproducible manner in the methods section. This should include an explanation of how the AI or AI-assisted tools were used in the image creation or alteration process, and the name of the model or tool, version and extension numbers, and manufacturer. Authors should adhere to the AI software’s specific usage policies and ensure correct content attribution. Where applicable, authors could be asked to provide pre-AI-adjusted versions of images and/or the composite raw images used to create the final submitted versions, for editorial assessment.


New statistical guidelines

Editors of Adv Clin Exp Med are well aware that correct analysis of statistical data and reporting the results of such analysis is not easy even for experienced researchers – because we are dealing with really, not only ostensibly complicated matters. Specialists from the Centre for Statistical Analysis at the Wroclaw Medical University want to provide you as much help as guidance as possible – and prepared these detailed guidelines for all authors wishing to submit their manuscripts to our journal.

New statistical guidelines


Life it is not just a series of calculations and a sum total of statistics, it's about experience, it's about participation, it is something more complex and more interesting than what is obvious.

[Daniel Libeskind, American architect and thinker]


New guidelines for our peer-reviewers

The integrity of the publication process and the quick dissemination of research relies on timely, high-quality reviews. Your efforts in reviewing papers and book proposals are a crucial service to the academic community. Ensuring the utmost integrity and transparency when you review has a real impact on the quality of work in your field, and how quickly research reaches its audience. Thank you for considering your ethical responsibilities, and remember that you can always rely on Adv Clin Exp Med editors for advice and support on any ethical matter.

The editorial office of Adv Clin Exp Med respects authors’, editors’ and reviewers’ professional integrity and freedom of expression and does not intend to interfere in their professional opinions on reviewed papers. We emphasize the importance of section editors and reviewers in taking leadership or assuming the position of opinion leader in their field by encouraging peer researchers to improve their manuscripts to cutting-edge levels and directing them to future research. Therefore, we offer you these guidelines to help you in your important and highly valued task.

Guidelines for peer-reviewers


Increase of article-processing charge (APC)

Advances in Clinical and Experimental Medicine is a journal published in a golden open access model – each published paper is available online at no cost, without any embargos, subscriptions or paywalls. Everyone can access and download it without any restrictions. However, such a model requires an article-processing charge (APC) since the journal receives no payments from the readers. The APC is payable per the accepted article. Our APC is calculated to contribute to the costs associated with the publication process from peer review of the submitted manuscript, through to copy-editing and typesetting, to online hosting and dissemination of the published article. It is a prerequisite to ensure the unrestricted dissemination of your research in the scientific community and beyond. Therefore, from March 1, 2024 [Friday], 0:01 CET, our APC will increase.


The publication fee for manuscripts submitted since March 1, 2024 is:

1600 EUR / 6900 PLN for all types of papers.

We DO NOT charge publication fees for invited editorial and editorial commentaries.


If the paper was submitted until February 29, 2024, the following APCs apply:

– 990 EUR / 4900 PLN for original papers and meta-analyses;

– 700 EUR / 3500 PLN for reviews;

– 350 EUR / 1750 PLN for research-in-progress (RIP) papers and research letters.


The publication fee for manuscripts submitted until January 31, 2023 is:

– 700 EUR / 3500 PLN for original papers, meta-analyses and reviews;

– 350 EUR / 1750 PLN for research-in-progress (RIP) papers and research letters.


You do the research – we take care of the text

There are additional fees for the following optional services (if ordered by the Authors of the manuscript accepted for publication):

  • 200 EUR / 880 PLN for linguistic editing;
  • 200 EUR / 880 PLN for technical editing.

Services offered

Linguistic editing ensures that the English language of your manuscript is of the academic standard required for publication in our journal. It comprises correcting grammar, punctuation and spelling errors, pointing to inconsistencies, as well as removing or reformulating awkward or ambiguous sentences, while keeping, where possible, your voice and choice of words. We also suggest discipline-specific terms. In the proof sent to you, all our comments and doubts are clearly marked, so that you could make the necessary corrections.

Technical editing ensures that the structure of your manuscript follows the Adv Clin Exp Med house style. We reformat references (both in the text and the whole reference list) and look for missing information in the reference section. We improve the overall presentation by revising titles/subtitles, font, spacing, text alignment, and paragraph structure. We also edit equations and tables, and produce publication-ready figures that clearly communicate your research to readers. Figure editing enhances your charts and graphs, as well as graphical abstracts; it comprises revising the text included, colors, shading, border, size, resolution, and file type. 

You can choose either or both of the abovementioned optional services, or decline them. When submitting the manuscript to Adv Clin Exp Med via the Editorial System, you will be provided with special checkboxes to select if needed. Following the acceptance of your article for publication, you will be asked to pay the basic APC and the additional fees for the chosen editing services.

Please be informed that the articles finally published in Adv Clin Exp Med must comply with the high standards of the journal.

More information: Managing Editor [


Our new requirements concerning figures

We implemented new requirements regarding figures – they stem from stipulations issued by databases and digital archives in which our journal is indexed.


We accept up to 10 figures (2 figures in Research letters). Overtly complex figures will be divided into smaller ones and the number of figures will be counted again. A single figure can have no more than 6 panels (A–F). One panel means one chart – multiple small charts cannot form one panel.

All elements of each figure must be legible when viewed on an A4 page in a PDF file in full-screen mode, without zooming. Overtly complex figures with multiple charts/graphs combined into one panel cannot fulfill this requirement. Figures of low quality cannot be published, and consequently, papers with low-quality figures will not be published, even if accepted by peer reviewers.

Figures should be placed in separate files, not pasted into the main body of the text. Name your figure files with "Fig" and the figure number, e.g., Fig.1.tiff.

References to Figures should be placed according to the sequence of citing them in the manuscript. The text should include references to all figures.

Each figure should have a concise, self-explanatory caption describing accurately what the figure depicts. Captions for the figures should be placed at the end of the main body of the text. Do not embed the legend in the figure file. When applicable, be sure that both the figure captions and the figures themselves contain corresponding labels for multiple parts. Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs. If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves. All abbreviations used in a given table/figure should be explained below it or in the caption, even if a given abbreviation has already been explained in the text.

If Authors used in the work any figures, photographs, charts, tables, etc. which are not their work, and are protected by the copyright law, they shall be obliged to provide the Publisher with a written authorization to use such materials issued by the author’s economic rights holders. Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption.



XXVII Symposium of the Polish Society of Pediatric Endocrinology and Diabetology

With a great joy we would like to invite to Wrocław to participate in XXVII SYMPOSIUM OF THE POLISH SOCIETY OF PEDIATRIC ENDOCRINOLOGY AND DIABETOLOGY on October 24-26, 2024.


The dynamic development of all fields of medicine is a challenge for every physician, often changing the perspective on things that seem to be known and beyond doubt. Therefore, for 3 days, we will discuss about current diagnostic and therapeutic problems in endocrinology and pediatric diabetology. We believe that in the Symposium program we will find answers to difficult questions in the context of new challenges.

We invite to Wrocław, one of the most beautiful cities in Poland - not without reason called the Venice of the North or the Amsterdam of the East. Famous for dozens of bridges and islands on the Odra river, a collection of dwarfs, diverse architecture and modernity. But above all, we invite you to Wrocław as a friendly city and a city that unites, a city called a city of meetings - people and ideas.


Prof. Robert Śmigiel

Department of Pediatrics, Endocrinology, Diabetology and Metabolic Diseases
Wroclaw Medical University

Chairman of the Scientific and Organizational Committee



Altmetric on Advances in Clinical and Experimental Medicine

We’ve chosen to embed Altmetric Badges on our publications to help authors track the attention their research is receiving. By tracking unique identifiers such as DOIs, Altmetric collects article-level metrics and online conversations around articles published in Adv Clin Exp Med. Online mentions that contain links to the abstract landing page are picked up and collated, and the result is the Altmetric Attention Score and Badge.

You will find the Altmetric Badge at the top of each article’s page. When you click on the Altmetric Badge, you will be directed to the Altmetric Details Page, which will show you every mention for your article across Twitter, blogs, mass media outlets, Facebook, and more. View this video for an overview of the Altmetric Details Page.


Why use Altmetric?

Altmetrics can be useful to researchers who are keen on (1) building their online presence, (2) demonstrating the broader impact of their work, and (3) communicating the story of their research to grant review committees and panels. To leverage this information, consider using Altmetric data to:

  • Identify coverage and wider dissemination of your research to use as evidence in CVs or funding applications;
  • View who is talking about your research, and identify potential new collaborators and build relationships with key influencers;
  • Monitor other research in your field and see how it has been received by a broader audience;
  • Manage your online reputation, and actively engage with comments and conversation about your work.



Our rules concerning corrections, retractions and removals

The editorial office of Adv Clin Exp Med will carefully consider complaints, appeals and allegations in line with guidance from the Committee on Publication Ethics (COPE). This applies both pre- and post-publication. Authors, readers or institutions can lodge complaints.


Our rules concerning appeals

The authors have the right to appeal against a rejection from Adv Clin Exp Med. An appeal is an extension of the peer review process, and the same ethical standards apply, so a request should not be submitted whilst the manuscript in question is under consideration by another publication.


Our rules concerning commentaries and discussions

Commentaries are short articles which outline an observation on a published article. If a researcher wishes to comment on a paper published in Adv Clin Exp Med, before formal submission, they should contact the journal with a pre-submission enquiry: [Managing Editor Marek Misiak, OR]. If approved for submission as a Commentary, they will be then invited to publish a brief commentary article, which will be bi-directionally linked to the original paper it discusses. A Commentary should consist of up to 1500 words, excluding references, and at most 2 tables or figures (2 tables and 2 figures at most in one paper). The number of references is not limited. A Commentary can have up to 2 authors. Commentaries should be written in a neutral tone, and must relate to the original published article. All such articles considered for publication will be subject to peer review, and the decision to accept or reject an article is at the editor’s discretion.

New call for submissions 

Innovations in Therapeutic Interventions: Advancing Clinical and Experimental Medicine

We welcome reviews as well as original research articles and research letters in various clinical and experimental medicine areas. We encourage submissions on the following topics:

Precision Medicine and Personalized Therapies: Explore novel approaches in tailoring medical treatments based on an individual's genetic makeup, environmental factors, and disease characteristics. Highlight the potential of precision medicine in improving patient outcomes and overcoming treatment challenges. This topic includes but is not limited to:

Immunotherapy and Immunomodulation: Investigate the role of immunotherapy and immunomodulation in treating various diseases, including cancer, autoimmune disorders, and infectious diseases. Focus on cutting-edge techniques, therapeutic targets and potential synergies with other treatment modalities.

Gene and Cell Therapies: Present innovative research on gene and cell-based therapies, such as stem cell transplantation, gene editing and regenerative medicine. Explore their applications across different diseases and discuss their clinical implications and prospects.

Artificial Intelligence and Big Data Analytics in Medicine: Examine the integration of artificial intelligence (AI) and big data analytics in medical research, diagnostics, treatment optimization, and patient care. Highlight the potential of AI algorithms, machine learning and data-driven approaches in revolutionizing healthcare practices.

Digital Health Technologies and Wearables: Discuss the advancements in digital health technologies (including telemedicine), wearable devices and remote monitoring systems. Explore their impact on healthcare delivery, patient engagement, disease management, and prevention strategies.


All papers should focus on:

Translational Research and Bench-to-Bedside Innovations: Showcase translational research efforts that bridge the gap between laboratory discoveries and clinical applications. Present successful examples of bench-to-bedside innovations that have improved patient care and outcomes.



therapeutic interventions; personalized therapies; immunotherapy; immunomodulation; gene and cell therapies; artificial intelligence; Big Data analytics; digital health technologies


Professor Jolanta Saczko is no longer with us

All members of the Editorial Committee and Editorial Board of Advances in Clinical and Experimental Medicine are deeply saddened by the news of Professor Jolanta Saczko’s passing on June 23, 2023. She was one of our Section Editors and our mainstay – committed, patient and extremely competent. On behalf of all abovementioned members, we extend our heartfelt condolences to the family, friends, and loved ones of Professor Saczko. We know that words can give little consolation to relieve grief but we should like you to know that we too will be grieving for her.

She will be greatly missed, but her legacy will live on for many years to come.

In deepest sympathy,

Prof. Donata Kurpas

Prof. Wojciech Kosmala
Deputy Editor

members of the Editorial Committee of Advances in Clinical and Experimental Medicine
members of the Editorial Board of Advances in Clinical and Experimental Medicine

Seamus Heaney
The Blackbird of Glanmore

On the grass when I arrive,
Filling the stillness with life,
But ready to scare off
At the very first wrong move.
In the ivy when I leave.
It’s you, blackbird, I love.
I park, pause, take heed.
Breathe. Just breathe and sit
And lines I once translated
Come back: “I want away
To the house of death, to my father
Under the low clay roof.”
And I think of one gone to him,
A little stillness dancer—
Haunter-son, lost brother –
Cavorting through the yard,
So glad to see me home,
My homesick first term over.
And think of a neighbour’s words
Long after the accident:
“Yon bird on the shed roof,
Up on the ridge for weeks—
I said nothing at the time
But I never liked yon bird.”
The automatic lock
Clunks shut, the blackbird’s panic
Is shortlived, for a second
I’ve a bird’s eye view of myself,
A shadow on raked gravel
In front of my house of life.
Hedge-hop, I am absolute
For you, your ready talkback,
Your each stand-offish comeback,
Your picky, nervy goldbeak—
On the grass when I arrive,
In the ivy when I leave.


ACEM is a signatory of San Francisco Declaration on Research Assessment (DORA), which intends to halt the practice of correlating the journal impact factor to the merits of a specific scientist's contributions. Such practice creates biases and inaccuracies when appraising scientific research. It also states that the impact factor is not to be used as a substitute measure of the quality of individual research articles, or in hiring, promotion, or funding decisions. It has become a worldwide initiative covering all scholarly disciplines and all key stakeholders including funders, publishers, professional societies, institutions, and researchers. We encourage all individuals and organizations who are interested in developing and promoting best practice in the assessment of scholarly research to sign DORA.

Its objectives are:

1. Raise awareness. To call attention to new tools and processes in research assessment and the responsible use of metrics that align with core academic values and promote consistency and transparency in decision-making.

2. Facilitate implementation. To aid development of new policies and practices for hiring, promotion, and funding decisions.

3. Catalyze change. To spread research assessment reform broadly by working across scholarly disciplines and globally.

4. Improve equity. To call for broader representation of researchers in the design of research assessment practices that directly address the structural inequalities in academia.

How Journals and Publishers Can Help to Reform Research Assessment?


Using bar and line graphs to present statistical data

Figures in scientific publications are critically important because they often show the data supporting key findings. However, small sample size studies rarely include scatterplots, box plots and histograms that allow readers to critically evaluate continuous data. Most papers present continuous data as bar and line graphs. This is problematic, as many different data distributions can lead to the same bar or line graph. The full data may suggest different conclusions from the summary statistics.

This issue is concisely discussed [with examples] in this paper:

It is also worthy to read this paper:


Support from the Ministry

Our journal has received financial support within the “Social Responsibility of Science – Support for Academic Publishing” project based on agreement No. RCN/SP/0584/2021 from the resources of Ministry of Science and Higher Education.

Scientific Social Responsibility programs – Science for All – constitute an important offer for society. They aim at identifying opportunities, supporting dialogue and engaging large groups of stakeholders. Science for All increases the efficiency and effectiveness of activities in science and research areas, implementing the University’s Third Mission.

Not only does Science for All popularize and disseminate science but also stimulates cognitive curiosity and integrate local communities with academia. The Science for All initiatives are supposed to equal educational opportunities and reach those parts of the country where academic and scientific activity has not existed so far.


How to create an account in Editorial System?

The editorial staff of Advances in Clinical and Experimental Medicine is aware that creating an account in the Editorial System [], which we use, i.a., for manuscript and review submission, is not always easy from the perspective of authors and peer reviewers. Therefore, we offer a guideline in PDF linked below, which presents the whole process using screenshots and comments.

Guideline – how to create an account in Editorial System

Should any problems arise, do not hesitate to contact the managing editor of Advances in Clinical and Experimental Medicine – Marek Misiak []. He will establish an account for you and will only need to log in.



The editorial office of Advances in Clinical and Experimental Medicine proudly informs that the journal has been accepted into Directory of Open Access Journals (DOAJ) and is indexed in this database. This fact confirms our integrity regarding publication ethics and clear rules for authors.


Our support for Ukraine

The 19th-century Ukrainian Romantic poet, Taras Shevchenko (1814–1861), wrote this poem in 1845:


Як умру, то поховайте
Мене на могилі
Серед степу широкого
На Вкраїні милій,
Щоб лани широкополі,
І Дніпро, і кручі
Було видно, було чути,
Як реве ревучий…

When I die, let me rest
Buried in a grave
On the wide steppe
In my dear Ukraine,
Where the broad-rimmed fields
And the Dnipro, and cliffs
Are visible, so I can hear
How the roaring roars.


Shevchenko’s “Testament” remains an anthem for Ukrainian national sentiment. It’s a poem of longing, written by a man who is separated from his native rivers, cliffs, and steppe. It shows off the alliterative power of the Ukrainian language.

After a Russian-language Odessa poet, Boris Khersonsky, began to write poems in Ukrainian in solidarity with the 2013–2014 Maidan “Revolution of Dignity,” he wrote a version of “Testament.”


Як умру, то не ховайте
мене на могилi.
Хай несуть мене до неба
полум’янi хвилi.
Хай розвiє сiрий попiл
повiтряна сила,
бо йому, щоб полетiти,
не потрiбнi крила.
Бо нема землi на свiтi,
щоб назвав своею.

When I die, don’t let me rest
Buried in a grave
Let the waves of fire carry
Me up to the sky.
Let the windy powers dispel
The gray ash, let it scatter
For, no wings are necessary
For this ash to fly.
For no land in all the world
Can be called my own.